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Abstract 
Ebolavirus is a highly lethal hemorrhagic disease virus that most recently was responsible for 25 
two independent 2014 outbreaks in multiple countries in Western Africa, and the Democratic 
Republic of the Congo. Herein, we show that a cytomegalovirus (CMV)-based vaccine 
provides durable protective immunity from ebolavirus following a single vaccine dose. This 
study has implications for human ebolavirus vaccination, as well as for development of a 
‘disseminating’ vaccine to target ebolavirus in wild African great apes.  30 
 
The original zoonotic source of the 2014  Zaire ebolavirus (ZEBOV) outbreak in Western 
Africa is currently unclear (1, 2). Following transmission into the human population, the chain 
of ebolavirus infection is maintained by human-to-human transmission. Contact with wild 
animals serves as a main conduit for the initial zoonotic transmission of ebolavirus into the 35 
2 
 
human population (2-7). Fruit bats are believed to be a main source of human infection, and 
direct contact or exposure to environments inhabited and frequented by bats has been 
associated with human outbreaks (2, 4, 7). Great apes (western lowland gorillas and 
chimpanzees) are a second significant source of transmission due, in large part, to the 
bushmeat trade which drives humans and wild animals together within an environment 40 
conducive to zoonotic transmission (i.e., hunting and butchering) (3-5).  Consistent with the 
importance of this route for zoonotic transmission of ebolavirus, a 2014  ZEBOV outbreak in 
the Boende Health Zone in the Equateur Province in the Democratic Republic of Congo, 
independent from the West Africa epidemic, was a result of handling and preparation of 
bushmeat (8). Ebolavirus is highly lethal in African great apes, and is regarded as a major 45 
threat to the survival of chimpanzees and gorillas in the wild (3, 5, 9-12). Vaccination of great 
apes has been proposed as one strategy to decrease the transmission of ebolavirus to humans, 
whilst at the same time also protecting these wild animal populations from the devastating 
effects of ebolavirus (4, 13, 14). We recently proposed the use of a CMV-based 
‘disseminating’ vaccine as one approach to achieve vaccine coverage in the inaccessible and 50 
hostile environment of African tropical forest regions, where application of conventional 
vaccines using baiting/individual darting strategies may prove more difficult, if not 
impossible (14). CMV is a species-specific β-herpesvirus that is benign except in the 
immunocompromised host, such as individuals undergoing iatrogenic immunosuppression, 
AIDS patients (prior to HAART) and the neonate (15). CMV is also highly immunogenic, and 55 
has shown promise for development as a vaccine vector platform (16-20). We hypothesize 
that amongst other ebolavirus vaccine platforms, the established ability of CMV to spread 
easily through its host population regardless of CMV immune status (14, 21-24) makes this 
vector platform suited for development as a ‘disseminating’ ebolavirus vaccine that could 
spread ebolavirus-specific immunity from animal-to-animal without the need for direct 60 
vaccination of every individual. CMVs are extremely host specific (25, 26). In a previous 
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study we showed the ability of a single dose of a murine CMV (MCMV) expressing a CD8 T 
cell epitope from nucleoprotein (NP) of ZEBOV (MCMV/ZEBOV-NPCTL) to induce durable 
ZEBOV-specific CD8
+
 T cell immunity for at least 33 weeks (> 8 months) post-vaccination 
(14). In this earlier study, mice vaccinated with MCMV/ZEBOV-NPCTL were protected 65 
against disease when challenged with a lethal ZEBOV dose of mouse-adapted ZEBOV (ma-
ZEBOV) at 6 weeks post-boost. Previous studies using MCMV recombinants expressing 
pathogen target epitopes (influenza A and lymphocytic choriomeningitis virus) have shown 
long-lasting protective immunity (27). In the current study, we wanted to assess whether 
MCMV/ZEBOV-NPCTL was able to afford durable protective immunity against a lethal 70 
ZEBOV challenge after only a single vaccine dose. We reasoned that the capacity to provide 
such long-lasting protective immunity would be an attractive if not essential quality for 
development of CMV as either a ‘disseminating’ vaccine for use in wild African great ape 
populations, or as a human CMV-based vaccine for conventional use. Animal use complied 
with the Guide for the Use and Care of Laboratory Animals, USDA Animal Welfare 75 
Regulations, PHS Policy on Humane Care and Use of Laboratory Animals and other relevant 
regulations. All procedures received prior approval by IACUC committees at RML, DIR, 
NIAID, NIH and OHSU. Figure 1 shows a schematic of the mouse-adapted (ma)-ZEBOV 
challenge study using MCMV/ZEBOV-NPCTL vaccinated mice. To assess whether vaccine-
induced immunity provided durable protection, we challenged mice at 119 days (17 weeks) 80 
post-vaccination. This time of challenge was based on the observation that most previous 
mouse studies (ours included (14)) have only looked at short-term protection, within 6 weeks 
following the last vaccine dose (28-30). Briefly, female C57BL/6 mice were vaccinated intra-
peritoneally (IP) with either MCMV/ZEBOV-NPCTL (Clone 5A1) (5x10
5
 plaque-forming 
units, pfu), parental MCMV wild-type (MCMV WT), or vaccine diluent (2% FBS in DPBS) 85 
(Mock). Excepting a mouse receiving MCMV WT (which died during the vaccine phase) 
CD8
+
 T cell responses were assessed in mice (n = 4-5) 8/9 and 14 weeks after vaccination 
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(Figure 2B & C). The gating strategy is shown for a representative MCMV/ZEBOV-NPCTL 
vaccinated mouse in Figure 2A. Consistent with our earlier study, MCMV/ZEBOV-NPCTL 
induced ZEBOV NP-specific CD8
+
 T cells, which were not observed in either MCMV WT or 90 
Mock controls. All MCMV WT and MCMV/ZEBOV-NPCTL, but not Mock groups also had 
responses against MCMV endogenous proteins M38 and M45 as expected. At week 17 
(approx. 4 months) post-vaccination, age-matched mice (n=14) were challenged with 1x10
3
 
LD50 ma-ZEBOV (IP). An additional control group of mice (n=14) received the ‘benchmark’ 
VSVΔG/ZEBOVGP vaccine (31) to serve as a vaccine efficacy control. Vaccine efficacy was 95 
assessed on the basis of morbidity (clinical symptoms and weight loss) and survival (Figure 
3). Weight was monitored in mice until day 17 post-challenge, or until all animals had 
succumbed to ZEBOV disease. Surviving mice were then followed until days 28 or 29 post-
challenge, at which time they were humanely euthanized. All MCMV WT and Mock control 
mice showed signs of severe ma-ZEBOV disease with clinical symptomology (ruffled hair, 100 
reduced mobility and weight loss). 100% of Mock and 90% of MCMV WT mouse groups 
perished as a result of ZEBOV-associated disease by day 7 post-challenge (Figure 3A). In 
contrast, no ZEBOV disease was observed in MCMV/ZEBOV-NPCTL vaccinated mice. 
Although not statistically significant, MCMV/ZEBOV-NPCTL vaccinated mice did show a 
slight loss in weight suggesting that immunity was not sterilizing in all mice (Figure 3B), 105 
which is consistent with results from the earlier study (14). Together, these results indicate 
that a CMV-based ZEBOV vaccine can provide long-term protection from ZEBOV-
associated disease and mortality following only a single inoculation at least 119 days (approx. 
4 months) post-vaccination. Although a role for antibodies cannot be formally discounted in 
this protection, the expression of only a single CD8 T cell ZEBOV epitope by 110 
MCMV/ZEBOV-NPCTL, the absence of detectable ZEBOV antibodies in vaccinated mice 
prior to challenge (Table 1) and the presence of ZEBOV NP-specific CD8
+
 T cell responses 
(Figure 2) are consistent with the mode of protection induced by the CMV vector as being 
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primarily T cell mediated. CMV has been shown to induce T cell responses shifted towards 
‘effector’ memory (TEM) that are primed for immediate ‘effector’ function at 115 
mucosal/epithelial tissue sites (32-34). We previously showed that ZEBOV NP CD8
+
 T cell 
responses had TEM characteristics based on similarity in kinetics of expansion as a MCMV 
‘inflationary’ endogenous protein (M38) (14). Using the same study group from this earlier 
published study (Figure 2 in (14)), splenocytes were harvested at days 442 and 444 (> 14 
months) following a single MCMV/ZEBOV-NPCTL IP vaccination (1x10
5
 pfu). Antigen-120 
specific CD8
+
 T cell responses were then phenotyped into TEM and TCM on the basis of CD44, 
a marker of antigen-experience (35), and KLRG-1, a marker of CMV- as well as other 
herpesvirus-specific CD8
+
 TEM found consistently upregulated to high levels on these cells 
(36, 37).  As shown in Figure 4, ZEBOV NP-specific CD8
+
 T cell responses were comparable 
to the TEM-biased responses directed against M38 rather than to the central memory (TCM) 125 
responses against M45. In summary, we show that a CMV-based ebolavirus vaccine can 
provide durable immunity for at least 119 days following only a single vaccine dose. These 
findings have important implications for development of CMV as a disseminating vaccine to 
prevent ebolavirus in great apes, and possibly a human CMV (HCMV)-based ebolavirus 
vaccine for humans. Studies ongoing will determine whether these results translate to 130 
protection in the macaque ebolavirus challenge model, regarded as the ‘gold standard’ for 
vaccine efficacy assessment in a model representative of ebolavirus infection in great apes, 
including humans.    
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 Figure 1.  Schematic showing mouse groups and sampling regimen in ma-ZEBOV 
challenge study of MCMV/ZEBOV-NPCTL. C57BL/6 (H2
b
-restricted) mice were 
immunized using a single IP dose of 5x10
5
 pfu of MCMV/ZEBOV-NPCTL. Control groups 
received MCMV WT or diluent (Mock). Splenocytes were harvested for analysis of T cell 285 
responses in groups of mice at times indicated (week 8/9: days 56, 58, 65 post-vaccination, 
and prior to challenge: days 96 and 100 post-vaccination). Antigen specific T cells were 
assayed by using ICS with a 6 hour incubation in the presence of BFA with peptide. After 119 
days (> 4 months) post-vaccination, mice were challenged with 1x10
3
 LD50 ma-ZEBOV IP 
and disease course was followed for 28 days. VZVΔG/ZEBOVGP vaccinated mice served as 290 
a vaccine efficacy control group, and received a single IP dose of VZVΔG/ZEBOVGP (5x105 
pfu) prior to the ma-ZEBOV challenge (47 days later).   
 
Figure 2. CD8
+
 T cell responses following immunization with MCMV/ZEBOV-NPCTL. 
Female C57BL/6 H2
b
-restricted mice were immunized IP using a single inoculation of 5x10
5
 295 
pfu of MCMV/ZEBOV-NPCTL. Control groups received MCMV WT (5x10
5
 pfu) or diluent 
(Mock).  Splenocytes were harvested for analysis of T cell responses. (A) Schematic showing 
gating strategy for ICS. NP-specific T cells for a representative MCMV/ZEBOV-NPCTL 
vaccinated mouse is shown. (B) 8/9 weeks (days 56, 58 and 65 post-vaccination), and (C) 
week 14 (days 98 and 100 post-vaccination). T cells were analyzed by using ICS with a 6 300 
hour incubation in the presence of BFA with indicated peptide as previously described (14). 
Human prostate-specific antigen (PSA) is an irrelevant control peptide (20), and NP (peptide 
pool) is an overlapping peptide pool (15-mer, 5 amino acid overlap) representing the full 
length ZEBOV NP protein. All mice receiving MCMV had CD8
+
 T cell responses against 
MCMV M38 and M45, MCMV endogenous ‘inflationary’ and ‘non-inflationary’ antigens, 305 
respectively. Mock-infected mice showed no MCMV-specific T cell responses as expected. 
All MCMV/ZEBOV-NPCTL immunized mice showed significant CD8-restricted T cell 
13 
 
responses against the NP target antigen (2-tailed t-test, p<0.05) consistent with previous 
results (14). All mice were 29 weeks old at time of vaccination other than the Mock group 
assessed at Week 14, which were 21 weeks old.  = not tested. 310 
 
Figure 3. Efficacy of MCMV/ZEBOV-NPCTL vector against ma-ZEBOV challenge 
following a single inoculation at day -119. Age matched groups of C57BL/6 mice (n=10) 
were vaccinated with a single IP administration of 5x10
5
 pfu of MCMV/ZEBOV-NPCTL. 
Additional groups received either diluent (Mock), or VSVΔG/ZEBOVGP (positive control for 315 
vaccine efficacy, given 47 days prior to challenge). After 119 days, mice were challenged 
with 10
3
 LD50 ma-ZEBOV (IP). Data represent (A) Percent survival. (B) Body weight change 
over time post-challenge. For body weight, groups were weighed daily until 17 days post-
EBOV challenge, or until all animals in a group had succumb to ZEBOV disease. Vaccination 
with MCMV/ZEBOV-NPCTL had a significant impact on survival from ma-ZEBOV challenge 320 
compared to MCMV WT control (p <0.0001) using a Log-rank (Mantel-Cox) Test. MCMV 
WT and Mock groups showed a significant decrease in bodyweight compared to 
MCMV/ZEBOV-NPCTL (p-value at least <.05) from day 3 onwards using a one-tailed t-test. 
No significant differences were seen in body weight between MCMV/ZEBOV-NPCTL and 
VSVΔG/ZEBOVGP groups at any time post-challenge. All mice were 21 weeks old at time of 325 
vaccination. 
 
Figure 4. MCMV/ZEBOV-NPCTL induces TEM-biased responses against ZEBOV NP. 
129S1/SvlmJ/Cr H2
b
-restricted mice were immunized (IP) with a single dose (1x10
5
 pfu) of 
MCMV/ZEBOV-NPCTL (clone 5D1). These mice are the same groups that were serially 330 
followed for T cell responses through week 33 post-vaccination in reference (14). (A) At days 
442 and 444 (> 14 months) post-vaccination, splenocytes were harvested and CD8
+
 T cell 
responses were determined by ICS using a 6 hour incubation in the presence of BFA with 
14 
 
peptides (NP, M38 or M45). (B) ZEBOV NP-specific CD8
+
 T cell (IFN
+
/TNF
+
) responses 
were characterized into TEM and TCM on the basis of CD44 and KLRG-1 expression. M38 and 335 
M45 responses served as controls for TEM and TCM-biased responses, respectively. All 
responses were normalized against cells incubated in the absence of peptide. Typical response 
(B and C) and (D) average responses in total mice tested (n=6) with SD shown. Populations 
were compared using 1-way ANOVA with Bonferroni’s Post Test.    
 340 
Table 1. Total anti-ZEBOV VLP IgG antibody titre in mouse blood samples pre- and 
post-challenge.  VLPs (GP/NP/VP40) were used as the source of antigen. Pre-challenge 
Mock samples were used to establish background values. Samples were deemed positive if the 
signal was greater than the mean of pre-challenge Mock values plus four standard deviations.  
An ‘in house’ anti-VP40 antibody was used as the positive control. NT = not tested. Samples 345 
from 4 mice of each experimental group were analyzed. 
